Chemotherapy, Cancer, Regional Perfusion
"Chemotherapy, Cancer, Regional Perfusion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
MeSH Number(s)
E02.319.267.200
E04.292.425
Concept/Terms
Chemotherapy, Cancer, Regional Perfusion- Chemotherapy, Cancer, Regional Perfusion
- Regional Perfusion Antineoplastic Chemotherapy
- Isolation Perfusion Cancer Chemotherapy
- Cancer Chemotherapy, Regional Perfusion
- Perfusion Cancer Chemotherapy, Regional
- Regional Perfusion Cancer Chemotherapy
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Cancer, Regional Perfusion".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Cancer, Regional Perfusion".
This graph shows the total number of publications written about "Chemotherapy, Cancer, Regional Perfusion" by people in Harvard Catalyst Profiles by year, and whether "Chemotherapy, Cancer, Regional Perfusion" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2013 | 3 | 0 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 1 | 4 |
| 2018 | 0 | 3 | 3 |
| 2019 | 8 | 3 | 11 |
| 2020 | 3 | 8 | 11 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
Below are the most recent publications written about "Chemotherapy, Cancer, Regional Perfusion" by people in Profiles.
-
Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative. Ann Surg Oncol. 2024 May; 31(5):3314-3324.
-
Influence of insurance status on the postoperative outcomes of cytoreductive surgery and HIPEC. J Surg Oncol. 2023 Mar; 127(4):706-715.
-
A total neoadjuvant chemotherapy approach is associated with improved recurrence-free survival in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and HIPEC. J Surg Oncol. 2023 Mar; 127(3):442-449.
-
Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study. J Gastrointest Surg. 2022 12; 26(12):2569-2578.
-
Feasibility of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced peritoneal surface tumors during the COVID-19 pandemic: A single-institution experience. J Surg Oncol. 2022 Dec; 126(8):1375-1382.
-
Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. Ann Surg Oncol. 2021 Aug; 28(8):4499-4507.
-
Fertility after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A call to action. J Surg Oncol. 2021 Mar; 123(4):1045-1049.
-
The role of molecular biomarkers in outcomes and patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin. Surgeon. 2021 Dec; 19(6):e379-e385.
-
CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Ann Surg Oncol. 2020 Dec; 27(13):4996-5004.
-
A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. J Surg Oncol. 2021 Jan; 123(1):187-195.